BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Teligene US readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Teligene US's drugs run\, from Cl
 inicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05168566-2749@assetmemo.bio
DTSTAMP:20261121T005833Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Sutetinib: Phase 2 readout est. (NCT05168566)
DESCRIPTION:Sutetinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Study
  to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic N
 on-small Cell Lung Cancer\nEstimated primary completion: December 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/sutetinib#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT05168566
URL:https://assetmemo.bio/drug/sutetinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06010329-2749@assetmemo.bio
DTSTAMP:20261121T005833Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Sutetinib: Phase 2 readout est. (NCT06010329)
DESCRIPTION:Sutetinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A Stu
 dy to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Loc
 ally Advanced or Metastatic NSCLC\nEstimated primary completion: December 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/sutetinib#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT06010329
URL:https://assetmemo.bio/drug/sutetinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
